imipramine and acebutolol

imipramine has been researched along with acebutolol in 24 studies

Research

Studies (24)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (58.33)	29.6817
2010's	8 (33.33)	24.3611
2020's	2 (8.33)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA	1
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL	1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY	2
Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P	1
Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R	1
Abraham, MH; Acree, WE; Ibrahim, A	1
Lombardo, F; Obach, RS; Waters, NJ	1
Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M	1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM	1
Ahman, M; Holmén, AG; Wan, H	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Campillo, NE; Guerra, A; Páez, JA	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Gozalbes, R; Pineda-Lucena, A	1
Akamatsu, M	1
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K	1
Bellman, K; Knegtel, RM; Settimo, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Abadi, AH; Abdel-Halim, M; Engel, M; Fathalla, RK; Hammam, MA; Hartmann, RW; Hefnawy, A; Keeton, AB; Maher, A; Maxuitenko, Y; Piazza, GA; Racheed, NAS; Sigler, S	1
Bucki, A; Głuch-Lutwin, M; Jaromin, A; Jastrzębska-Więsek, M; Kołaczkowski, M; Mordyl, B; Partyka, A; Siwek, A; Walczak, M; Wesołowska, A; Zagórska, A	1

Reviews

1 review(s) available for imipramine and acebutolol

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

23 other study(ies) available for imipramine and acebutolol

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. Journal of medicinal chemistry, 2001, Jul-19, Volume: 44, Issue:15 Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water	2001
Cheminformatic models to predict binding affinities to human serum albumin. Journal of medicinal chemistry, 2001, Dec-06, Volume: 44, Issue:25 Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids	2001
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. Journal of medicinal chemistry, 2002, Jun-20, Volume: 45, Issue:13 Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding	2002
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5 Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution	2004
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability. Journal of medicinal chemistry, 2004, Mar-25, Volume: 47, Issue:7 Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties	2004
QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorganic & medicinal chemistry, 2007, Jun-01, Volume: 15, Issue:11 Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship	2007
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs. European journal of medicinal chemistry, 2008, Volume: 43, Issue:3 Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Determination of log D via automated microfluidic liquid-liquid extraction. Journal of medicinal chemistry, 2008, Aug-28, Volume: 51, Issue:16 Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics	2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship	2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6 Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorganic & medicinal chemistry, 2009, Oct-01, Volume: 17, Issue:19 Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Neural computational prediction of oral drug absorption based on CODES 2D descriptors. European journal of medicinal chemistry, 2010, Volume: 45, Issue:3 Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical	2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
QSAR-based solubility model for drug-like compounds. Bioorganic & medicinal chemistry, 2010, Oct-01, Volume: 18, Issue:19 Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water	2010
Importance of physicochemical properties for the design of new pesticides. Journal of agricultural and food chemistry, 2011, Apr-13, Volume: 59, Issue:7 Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic	2011
QSAR-based permeability model for drug-like compounds. Bioorganic & medicinal chemistry, 2011, Apr-15, Volume: 19, Issue:8 Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2011
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharmaceutical research, 2014, Volume: 31, Issue:4 Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation	2014
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity. Journal of medicinal chemistry, 2021, 04-22, Volume: 64, Issue:8 Topics: Animals; Blood Proteins; Celecoxib; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Half-Life; Humans; Isoenzymes; Mice; Mice, Inbred C57BL; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Protein Binding; Pyrazoles; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship	2021
Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia. European journal of medicinal chemistry, 2022, Apr-05, Volume: 233 Topics: Animals; Antipsychotic Agents; Dementia; Humans; Ligands; Mice; Phosphoric Diester Hydrolases; Serotonin	2022